We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cold Plasma Penetrates Deep into Tissue to Fight Cancer

By HospiMedica International staff writers
Posted on 08 Oct 2025

Cancer remains one of the most challenging diseases to treat, especially when malignant cells infiltrate deep into tissue layers where conventional therapies have limited reach. More...

While existing radiation and chemotherapy approaches can damage healthy cells, new strategies are needed to target tumor cells more precisely and reduce side effects. Now, new research has demonstrated that a novel approach using cold plasma can penetrate deep into biological tissue and effectively destroy cancer cells without harming surrounding structures.

Researchers at the Leibniz Institute for Plasma Science and Technology (INP, Greifswald, Germany), in collaboration with Greifswald University Hospital (Greifswald, Germany) and collaborators, have developed an innovative approach to fight cancer using medically approved cold plasma technology. The method employs ionized gas that generates reactive oxygen and nitrogen species, which are highly active molecules known to influence cell growth and death. The work was carried out using the certified plasma jet kINPen, a device capable of delivering therapeutic plasma safely to tissue surfaces and deeper layers.

The team designed new 3D tissue models made of hydrogels that mimic real tumor structures, allowing precise observation of plasma behavior inside tissue. This enabled them to track how far the reactive molecules penetrate and identify which species contribute most to tumor destruction. Contrary to earlier assumptions, hydrogen peroxide—the molecule previously thought to drive plasma’s anticancer effect—played only a minor role, while short-lived molecules such as peroxynitrite proved most effective, reaching several millimeters into tumor-like tissue.

In another experimental setup, plasma was applied to models simulating surgical wounds with residual tumor cells. The treatment significantly reduced surviving cancer cells, particularly those already invading nearby tissue. These findings, published in Trends in Biotechnology, indicate that plasma therapy could become a valuable complement to surgery by eliminating microscopic tumor remnants and reducing relapse risk.

The researchers suggest that this new understanding of plasma-tissue interactions will enable more precise control of medical plasma devices for specific cancer types. As the technology advances, it could lead to more effective and less invasive cancer treatments, improving recovery and minimizing collateral damage to healthy tissue. The method’s ability to act independently of hydrogen peroxide also opens new directions for optimizing plasma composition in therapeutic applications.

"Our results could significantly improve the medical application of plasma," said Prof. Dr. Sander Bekeschus, head of the Plasma Medicine research program at INP. "The better we understand which molecules are active in the tissue, the more precisely plasma devices can be used for specific types of cancer."

Related Links:
INP
Greifswald University Hospital


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.